Moleculin Q2 2023 Earnings Report
Key Takeaways
Moleculin Biotech reported its Q2 2023 financial results, with a focus on advancing its pipeline programs and addressing unmet medical needs in resistant cancers and viruses. The company's cash and cash equivalents were $32.2 million as of June 30, 2023, which is believed to be sufficient to meet projected operating requirements into the third quarter of 2024.
Reported preliminary efficacy data on Phase 1B/2 clinical trial with Annamycin in soft tissue sarcoma metastasized to the lungs, with 73% exhibiting stable disease after two cycles.
Announced successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML (MB-106) and opens the Phase 2 portion for recruitment.
Announced a preliminary CR/CRi rate of 33% in the Phase 1B portion of its MB-106 clinical trial.
Announced the publication of data from successful European Phase 1 clinical trial evaluating Annamycin as single agent treatment of relapsed or refractory acute myeloid leukemia in the British Journal of Cancer Research.
Moleculin
Moleculin
Forward Guidance
Moleculin believes that its cash and cash equivalents of $32.2 million as of June 30, 2023 is sufficient to meet its projected operating requirements into the third quarter of 2024.